Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer

2023-506265-65-00 Protocol 42756493BLC1003 Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 7 Apr 2022 · Status Ongoing, recruitment ended · 2 EU/EEA countries · 14 sites · Protocol 42756493BLC1003

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 216
Countries 2
Sites 14

Localized Bladder Cancer

Key facts

Sponsor
Janssen - Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
7 Apr 2022 → ongoing
Decision date (initial)
2024-03-20
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-506265-65-00
EudraCT number
2021-004144-22

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Localized Bladder Cancer

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen - Cilag International

Sponsor organisation
Janssen - Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen - Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen - Cilag International
Contact name
CTIS Point of Contact

Locations

2 EU/EEA countries · 14 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruitment ended 17 7
Spain Ongoing, recruitment ended 26 7
Rest of world
Korea, Republic of, Canada, United States, Japan, Israel
173

Investigational sites

Germany

7 sites · Ongoing, recruitment ended
Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR
Klinik und Poliklinik für Urologie, Fetscherstrasse 74, Johannstadt-Nord, Dresden
Marien Hospital Herne Universitätsklinikum der Ruhr-Universität Bochum
Klinik fuer Urologie, Hoelkeskampring 40, 44625, Herne
Universitaetsklinikum Ulm AöR
Urologie- und Kinderurologie, Albert-Einstein-Allee 23, Eselsberg, Ulm
Universitaetsklinikum Muenster AöR
Klinik für Urologie und Kinderurologie, Albert-Schweitzer-Campus 1, Sentrup, Muenster
Universitaetsklinikum Frankfurt AöR
Klinik fuer Urologie, Theodor-Stern-Kai 7, 60590, Frankfurt Am Main
Urologicum Duisburg
Urologicum Duisburg, Fahrner Straße 123, 47169, Duisburg
Urologie Neandertal - Praxis Mettmann
Urologie Neandertal, Praxis Mettmann, Adlerstrasse 1, Nordrhein-Westfalen, Mettmann

Spain

7 sites · Ongoing, recruitment ended
Hospital Universitario 12 De Octubre
Servicio de Urología, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Universitario Fundacion Jimenez Diaz
Servicio de Urología, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Fundacion Instituto Valenciano De Oncologia
Oncology Deparmtent, Calle Professor Beltran Baguena 8, 46009, Valencia
Hospital Universitario La Paz
Servicio de Urología, Paseo De La Castellana 261, 28046, Madrid
Hospital Universitari Vall D Hebron
Servicio de Urología, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Hospital Universitario Reina Sofia
Servicio de Urología, Avenida Menendez Pidal S/n, 14004, Cordoba
Hospital Clinic De Barcelona
Servicio de Urología, Calle Villarroel 170, 08036, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2022-04-07 2022-04-07 2026-01-16
Spain 2022-04-08 2022-04-08 2026-01-16

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-14 Spain Acceptable
2024-03-18
2024-03-18
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-03-21 Spain Acceptable
2024-03-18
2024-03-21
3 SUBSTANTIAL MODIFICATION SM-1 2024-03-26 Spain Acceptable
2024-06-27
2024-06-27
4 SUBSTANTIAL MODIFICATION SM-2 2024-07-04 Spain Acceptable
2024-08-28
2024-08-30
5 SUBSTANTIAL MODIFICATION SM-3 2025-02-20 Spain Acceptable
2025-05-23
2025-05-26
6 SUBSTANTIAL MODIFICATION SM-4 2025-06-18 Spain Acceptable
2025-07-25
2025-07-28
7 SUBSTANTIAL MODIFICATION SM-5 2026-01-05 Spain Acceptable
2026-02-22
2026-02-24